Information Provided By: 
Fly News Breaks for February 5, 2018
PRTA
Feb 5, 2018 | 06:59 EDT
Cantor Fitzgerald analyst William Tanner cautions against "over-interpreting" the resignation of Prothena's Chief Medical Officer given the lack of details. The release of top-line data from the Phase 2b Pronto study has the ability to "clear the air" and assuage investor concerns, Tanner tells investors in a research note titled "PRONTO Trial Data Could Go A Long Way Toward Disproving A Negative." The analyst keeps an Overweight rating on the shares with a $65 price target.
News For PRTA From the Last 2 Days
There are no results for your query PRTA
